InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports 167% Revenue Growth, $8.32 Million in Committed Customer Orders

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company operating a contract development and manufacturing organization (“CDMO”) alongside an immunology-focused therapeutic development platform, reported revenue of $2.8 million for the nine months ended Sept. 30, 2026, up 167% from $1.05 million in the prior-year period. The increase reflects expansion of its CDMO operations, including the February acquisition of Recipharm Israel. The company reported an operating loss of $6.56 million and a net loss of $390,000, with the latter benefiting from a $6.4 million noncash bargain purchase gain related to the acquisition.

Scinai also reported approximately $8.32 million in committed customer orders as of Nov. 4, 2026, up more than 330% from year-end 2025, including an expanded U.S. customer agreement with approximately $5.1 million in committed base service fees. The company generated approximately $5.3 million in net proceeds from October financing transactions, bringing reported bank balances to approximately $8.1 million as of Oct. 27. Based on current projections and anticipated customer payments, Scinai expects sufficient operating liquidity through late 2027, with potential additional clinical manufacturing work that could extend its runway into 2028.

To view the full press release, visit https://ibn.fm/1OlnB

About Scinai Immunotherapeutics.

Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports 167% Revenue Growth, $8.32 Million in Committed Customer Orders.